

(Registration no. 1526)

# FINANCIAL STATEMENTS

for the year ended 31 December 2018

TRUSTEES	C Hector	Chairman - Employer Representative	
	N Moonia	Vice Chairman - Employer Representative	- resigned 1 October 2018
	D Radebe	Employer Representative	
	E Hlophane	Employee Representative	
	C Louw	Employee Representative	
	S Sohan	Employee Representative	
	K Madumo	Employee Representative	
	C McCrea-Phillips	Employer Representative	
	S Hoon	Employer Representative	- appointed 10 June 2018
	J Meiring	Pensioner Alternative Representative	
	JP Fegbeutel	Pensioner Member Representative	
	V Vatsha-Mahlaba	Co-opted Employer Representative	
	T Harakhchand	Alternative Employer Representative	
	K Kgomo	Alternative Employer Representative	- resigned 30 April 2018
	J Selumane	Alternative Employer Representative	
	M Gounden	Alternative Employer Representative	- appointed 1 October 2018
	G Shafee	Alternative Employer Representative	- appointed 1 October 2018

PRINCIPAL OFFICER AR Kelbrick

AUDITOR KPMG Inc.

Discovery Health Proprietary Limited 1 Discovery Place ADMINISTRATOR

Sandton 2146

Discovery Health Proprietary Limited 1 Discovery Place REGISTERED OFFICE

Sandton 2146

CONTENTS	Pages
Trustees' Responsibility and Approval	2
Statement of Corporate Governance by the Board of Trustees	3
Independent Auditor's Report	4 - 7
Statement of Financial Position	8
Statement of Comprehensive Income	9
Statement of Changes in Funds and Reserves	10
Statement of Cash Flows	11
Notes to the Financial Statements	12 - 44
Report of the Board of Trustees	45 - 53

(Registration no. 1526)

#### FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### TRUSTEES' RESPONSIBILITY AND APPROVAL

The Trustees are responsible for the preparation and fair presentation of the financial statements of BMW Employees Medical Aid Society, which comprise the statement of financial position at 31 December 2018, the statement of comprehensive income, the statement of changes in funds and reserves and the statement of cash flows for the year then ended, and the notes to the financial statements, which include a summary of significant accounting policies and other explanatory notes, in accordance with International Financial Reporting Standards (IFRS) and the requirements of the Medical Schemes Act of South Africa. In addition, the Trustees are responsible for preparing the report of the Board of Trustees.

The Trustees are also responsible for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and for maintaining adequate accounting records and an effective system of risk management.

The Trustees have made an assessment of the ability of the Scheme to continue as a going concern and have no reason to believe the Scheme will not be a going concern in the year ahead.

The auditor is responsible for reporting on whether the financial statements are fairly presented in accordance with the applicable financial reporting framework.

#### Approval of the annual financial statements

The annual financial statements of BMW Employees Medical Aid Society, as identified in the first paragraph, were approved by the Trustees on 23 April 2019 and are signed on their behalf by:

CHAIRMAN C HECTOR TRUSTEE S SOHAN PRINCIPAL OFFICER AR KELBRICK

(Registration no. 1526)

#### FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### STATEMENT OF CORPORATE GOVERNANCE BY THE BOARD OF TRUSTEES

The BMW Employees Medical Aid Society (the Scheme) is committed to the principles and practice of responsibility, accountability, fairness and transparency with its dealings with all stakeholders and applies good governance principles.

The Scheme is committed to ensure compliance with recognised framework and conducting affairs in accordance with ethical values, to ensure the adoption of risk assessment, evaluation and management processes with regular monitoring of third party administrators and providers in accordance with the service level agreements. This includes evaluating the performance of the Board and of the Board sub-committees against agreed terms of reference and performance targets, establishment and management of internal controls by assessing the adequacy and effectiveness through the reports of the internal auditors and calling on expert and professional advice when required. The Trustees are either appointed by the respective employers or elected by the members of the Scheme.

#### BOARD OF TRUSTEES

The Trustees meet regularly and monitor the performance of the Administrator and other service providers. They address a range of key issues and ensure that discussion of items of policy, strategy and performance is critical, informed and constructive.

All Trustees have access to the advice and services of the Principal Officer and consultants and, where appropriate, may seek independent professional advice at the expense of the Scheme.

## INTERNAL CONTROL

The Administrator of the Scheme maintains internal controls and systems designed to provide reasonable assurance as to the integrity and reliability of the financial statements and to safeguard, verify and maintain accountability for its assets adequately. Such controls are based on established policies and procedures and are implemented by trained personnel with the appropriate segregation of duties.

No event or item has come to the attention of the Trustees that indicates any material breakdown in the functioning of the key internal controls and systems during the year under review.

CHAIRMAN C HECTOR TRUSTEE S SOHAN PRINCIPAL OFFICER AR KELBRICK

23 April 2019



KPMG Inc. **KPMG Crescent** 85 Empire Road, Parktown, 2193, Private Bag 9, Parkview, 2122, South Africa Telephone Fax Docex Internet

+27 (0)11 647 7111 +27 (0)11 647 8000 472 Johannesburg kpmq.co.za

## **Independent Auditor's Report**

To the Members of BMW Employees Medical Aid Society

# Report on the Financial Statements

#### Opinion

We have audited the financial statements of BMW Employees Medical Aid Society (the Scheme), set out on pages 8 to 44, which comprise the statement of financial position at 31 December 2018, and the statement of comprehensive income, the statement of changes in funds and reserves and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, these financial statements present fairly, in all material respects, the financial position of BMW Employees Medical Aid Society at 31 December 2018, and its financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards and the requirements of the Medical Schemes Act of South Africa.

## Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Scheme in accordance with the Independent Regulatory Board for Auditors' Code of Professional Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of financial statements in South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (Parts A and B). We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

# Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

# Risk claims incurred

Refer to notes 1.9.1 and 9 to the financial statements.

The key audit matter	How the matter was addressed in our audit	
The most significant expense for the Scheme relates to risk claims incurred. Risk claims incurred is a key driver in determining the sustainability of the Scheme.	Our audit procedures included the following:  • We assessed the accuracy of benefit limits and rules captured onto the administration system by comparing the approved benefit limits and rules of the Scheme, to those captured onto the administration system.	

KPMG Inc. is a company incorporated under the South African Companies Act and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ("KPMG

Executive Chairman

Prof Wiseman Nkuhlu

International"), a Swiss entity

KPMG Inc. is a Registered Auditor, in public practice, in terms of the Auditing Profession Act, 26 of 2005

The company's principal place of business is at KPMG Crescent,

Registration number 1999/021543/21

85 Empire Road, Parktown, where a list of the directors' names is available



## The key audit matter

Due to the significant volume of claims processed by the Scheme the payment of valid risk claims is dependent on the integrity of the Scheme's administration system, as well as the automated claim assessment controls.

Risk claims incurred was considered a key audit matter due to the significant volume of claims processed during the year and the work effort required to be performed by the audit team.

#### How the matter was addressed in our audit

- We tested the IT controls in place to prevent unauthorised access to or changes to the administration system.
- We tested, through the assistance of our own IT specialists, the automated claim assessment controls of the administration system to ensure that only valid claims were being processed and paid.
- We inspected the reconciliation, performed by the Scheme administrator, between the administration system and the general ledger to assess whether the risk claims paid were accurately captured into the Scheme's accounting system.

# Outstanding risk claims provision

Refer to notes 1.6 and 5 to the financial statements.

#### The key audit matter

The outstanding claims provision (the provision) is the Scheme's estimate of the ultimate cost of settling all risk claims incurred but not yet reported (IBNR) at the reporting date.

The provision is determined by the Scheme's actuary as described in note 5 and is estimated using a range of statistical methods.

Determining the provision requires judgement with regard to the assumptions applied in respect of measuring the outstanding risk claims provision which could materially affect the financial statements.

Due to the involvement of the actuary and the significant estimation involved in determining the provision, this was considered a key audit matter.

#### How the matter was addressed in our audit

Our audit procedures performed included the following:

- We used our own actuarial specialists and:
  - evaluated the appropriateness of the methodology used in determining the provision.
  - challenged the appropriateness of the assumptions used in the Scheme's methodology for measuring the provision by evaluating the assumptions against best practice and the current economic environment.
  - evaluated the qualifications, competence, independence and integrity of the Scheme's actuary.
- We assessed the adequacy of the provision by comparing actual claims paid after year-end that related to the current year to the provision at year-end.
- We assessed whether the disclosures in the financial statements were appropriate in accordance with IAS 37 Provisions, contingent liabilities and contingent assets.



#### Other Information

The Scheme's trustees are responsible for the other information. The other information comprises the Trustees' Responsibility and Approval, the Statement of Corporate Governance by the Board of Trustees and the Report of the Board of Trustees. The other information does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Scheme's Trustees for the Financial Statements

The Scheme's trustees are responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards and the requirements of the Medical Schemes Act of South Africa, and for such internal control as the Scheme's trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Scheme's trustees are responsible for assessing the Scheme's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Scheme's trustees either intend to liquidate the Scheme or to cease operations, or have no realistic alternative but to do so.

#### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that
  are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness
  of the Scheme's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Scheme's trustees.
- Conclude on the appropriateness of the Scheme's trustees' use of the going concern basis of accounting
  and based on the audit evidence obtained, whether a material uncertainty exists related to events or
  conditions that may cast significant doubt on the Scheme's ability to continue as a going concern. If we
  conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the



related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Scheme to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Scheme's trustees regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

From the matters communicated with the Scheme's trustees, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

## Report on Other Legal and Regulatory Requirements

Non-compliance with the Medical Schemes Act of South Africa

As required by the Council for Medical Schemes, we report that there no material instances of non-compliance with the requirements of the Medical Schemes Act of South Africa, that have come to our attention during the course of our audit.

#### Audit tenure

As required by the Council for Medical Schemes' Circular 38 of 2018, *Audit Tenure*, we report that KPMG Inc. has been the auditor of BMW Employees Medical Aid Society for 11 years.

The engagement partner, BPK Jajula, has been responsible for BMW Employees Medical Aid Society's audit for one year.

KPMG Inc.



Per BPK Jajula Chartered Accountant (SA) Registered Auditor Director 30 April 2019

(Registration no. 1526)

# STATEMENT OF FINANCIAL POSITION

at 31 December 2018

	Notes	2018 R	2017 R
ASSETS Non-current assets Available-for-sale investments	2 [	127,942,836 127,942,836	110,037,922 110,037,922
Current assets Trade and other receivables Cash and cash equivalents Current, short term deposits and money market accounts Personal medical savings account	3 4	54,805,349 3,778,596 51,026,753 51,026,753	46,075,278 3,673,552 42,401,726 42,392,318 9,408
Total assets	=	182,748,185	156,113,200
FUNDS AND LIABILITIES  Members' funds  Accumulated funds  Available-for-sale reserve	[	175,689,014 163,388,998 12,300,016	149,341,258 130,815,400 18,525,858
Current liabilities Outstanding risk claims provision Personal medical savings account liability Trade and other payables	5 6 7	7,059,171 4,000,000 107,828 2,951,343	6,771,942 3,000,000 216,626 3,555,316
Total funds and liabilities	:	182,748,185	156,113,200



(Registration no. 1526)

# STATEMENT OF COMPREHENSIVE INCOME

for the year ended 31 December 2018

	Notes	2018 R	2017 R
Risk contribution income	8	172,756,552	155,624,921
Relevant healthcare expenditure Risk claims incurred Managed care: management services Claims recoveries from third parties Net income on risk transfer arrangement	9 12 10	(138,938,536) (138,149,864) (3,670,088) 2,050,256 831,160	(121,290,170) (122,759,917) (3,276,857) 4,174,635 571,969
Risk transfer arrangement fees Recoveries from risk transfer arrangement	11 11	(272,914) 1,104,074	(275,934) 847,903
Gross healthcare results		33,818,016	34,334,751
Administration expenditure Other operating expenses Net impairment on healthcare receivables	13 14	(7,602,488) (678,967) (1,945,106)	(6,788,446) (610,260) (1,218,467)
Net healthcare results		23,591,455	25,717,578
Other income Investment income Scheme funds Return on personal medical savings account Sundry income	15	9,672,285 9,643,204 9,643,204 29,081	3,728,276 3,715,903 3,678,127 37,776 12,373
Other expenditure Expenses for asset management services rendered Interest paid on personal medical savings account		(690,142) (690,142)	(596,584) (558,808) (37,776)
Net surplus for the year		32,573,598	28,849,270
Other comprehensive income Fair value adjustment on available-for-sale investments Realised gain on available-for-sale investments		(6,225,842) (994,322) (5,231,520)	7,843,860 7,990,714 (146,854)
Total comprehensive income		26,347,756	36,693,130



(Registration no. 1526)

# STATEMENT OF CHANGES IN FUNDS AND RESERVES

for the year ended 31 December 2018

	Accumulated funds	Available-for- sale reserve	Members' funds
	R	R	R
Balance at 1 January 2017	101,966,130	10,681,998	112,648,128
Total comprehensive income for the year	28,849,270	7,843,860	36,693,130
Net surplus for the year Other comprehensive income	28,849,270	7,843,860	28,849,270 7,843,860
Changes in fair value of available-for-sale investments Realised gains on disposal of available-for-sale	-	7,990,714	7,990,714
investments	¥	(146,854)	(146,854)
Balance at 31 December 2017	130,815,400	18,525,858	149,341,258
Total comprehensive income for the year	32,573,598	(6,225,842)	26,347,756
Net surplus for the year Other comprehensive income	32,573,598	(6,225,842)	32,573,598 (6,225,842)
Changes in fair value of available-for-sale investments	_	(994,322)	(994,322)
Realised gains on disposal of available-for-sale investments	-	(5,231,520)	(5,231,520)
Balance at 31 December 2018	163,388,998	12,300,016	175,689,014



(Registration no. 1526)

# STATEMENT OF CASH FLOWS

for the year ended 31 December 2018

Cash flows from operating activities  R R Cash flows from operations before working capital changes 17 24,777,060 25,906	,758
Cash flows from operations before working capital changes 17 24.777.060 25 906	,758
Working capital changes	***
- (Decrease) / increase in trade and other payables (603,973) 1,178	T. C
- Increase in outstanding risk claims provision 1,000,000 1,300	- N. C.
- Decrease in medical savings account liability (108,798) (959)	,895)
Cash generated by operations 23,151,784 27,716	,550
- Income from investments 4,372,479 3,514	,593
- Interest paid - (37	,776)
Net cash inflows generated from operating activities 27,524,263 31,193	,367
Cash flows from investing activities	
(Additions) to available-for-sale investments 2 (46,480,886) (25,941	.752)
	,158
	TR
Net cash outflow from investing activities (18,899,236) (25,462	,594)
Net increase in cash and cash equivalents 8,625,027 5,730	773
Net increase in cash and cash equivalents 8,625,027 5,730	1,772
Cash and cash equivalents at beginning of the year 42,401,726 36,670	,950
Cash and cash equivalents at end of the year 4 51,026,753 42,401	,726
Current, short term deposits and money market accounts 51,026,753 42,392	,318
Personal medical savings account - 9	,408



(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 1 PRINCIPAL ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these financial statements are set out below, and are consistent with last year unless otherwise stated.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the accounting policies. The notes to the financial statements set out those areas involving a high degree of judgement or complexity, or areas where assumptions and estimates are significant to the Scheme's financial statements.

#### 1.1 Basis of preparation

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) and the Medical Schemes Act of South Africa (the Act). The financial statements are prepared on the going concern principle using the historical cost basis, except for available-for-sale investments held at fair value.

These financial statements are presented in Rand, which is the Scheme's functional currency. Rounding of all amounts to the nearest Rand.

New standards, amendments and interpretations effective in 2018 and relevant to the Scheme

Title	Effective date - financial year commencing on
IFRS 7 - Disclosure Initiative - The amendments provide for disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities, including both changes arising from cash flow and non cash changes. This includes providing a reconciliation between the opening and closing balances for liabilities arising from financing activities. This standard had no significant impact on the 2018 financial statements.	1 January 2018
IFRS 9 Financial Instruments - IFRS 9, on 24 July 2014, the IASB issued the final IFRS 9 Financial Instruments Standard, which replaces earlier versions of IFRS 9 and completes the IASB's project to replace IAS 39 Financial Instruments: Recognition and Measurement. This standard will have a significant impact on the Scheme, which will include changes in the measurement bases of the Scheme's financial assets to amortised cost, fair value through other comprehensive income or fair value through profit or loss. Even though these measurement categories are similar to IAS 39, the criteria for classification into these categories are significantly different. In addition, the IFRS 9 impairment model has been changed from an "incurred loss" model from IAS 39 to an "expected credit loss" model, which is expected to increase the provision for bad debts recognised in the Scheme.  The standard is effective for annual periods beginning on or after 1 January 2018 with retrospective application, while early adoption is permitted.  IFRS 4 provides a temporary exemption that permits, but does not require, the scheme to apply IAS 39 rather than IFRS 9 for annual periods beginning before 1 January 2021.  A scheme may apply the temporary exemption from IFRS 9 if, and only if:  • it has not previously applied any version of IFRS 9  • its activities are predominantly connected with insurance at its reporting date.  The Scheme meets both the criteria and has decided to apply the exemption to defer the application of IFRS 9 to 1 January 2021.	1 January 2018



(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

New standards, amendments and interpretations not yet effective in 2018 and relevant to the Scheme:

Title	Effective date - financial year commencing on
IFRS 17 Insurance Contracts - IFRS 17 supersedes IFRS 4 Insurance Contracts and aims to increase comparability and transparency about profitability. The new standard introduces a new comprehensive model ("general model") for the recognition and measurement of liabilities arising from insurance contracts. In addition, it includes a simplified approach and modifications to the general measurement model that can be applied in certain circumstances and to specific contracts, such as:  Reinsurance contracts held;  Direct participating contracts; and  Investment contracts with discretionary participation features.  Under the new standard, investment components are excluded from insurance revenue and service expenses. Entities can also choose to present the effect of changes in discount rates and other financial risks in profit or loss or OCI.  The new standard includes various new disclosures and requires additional granularity in disclosures to assist users to assess the effects of insurance contracts on the entity's financial statements. The entity is in the process of determining the impact of IFRS 17 and will provide more detailed disclosure on the impact in future financial statements. The standard is effective for annual periods beginning on or after 1 January 2021. Early adoption is permitted.	l January 2021

The Scheme has not yet addressed the impact of these new standards and amendments.

#### 1.2 Classification, recognition, presentation and derecognition of financial instruments

The Scheme recognises a financial instrument when, and only when, it becomes a party to the contractual provisions of the instrument. The Scheme has the following financial instrument categories: available-for-sale investments, loans and receivables and financial liabilities. The Scheme has grouped its financial instruments into the following classes:

- · Available-for-sale investments;
- · Trade and other receivables;
- · Cash and cash equivalents;
- · Trade and other payables; and
- · Members' medical savings accounts.

The classification depends on the purpose for which the financial instruments are acquired. Management determines the classification of financial instruments at initial recognition. All purchases and sales of financial instruments are recognised on the trade date, which is the date on which the Scheme commits to purchase the financial asset or assumes the financial liability.

# Offsetting financial instruments

Where a current legally enforceable right of offset exists for recognised financial assets and financial liabilities, and there is an intention to settle the liability and realise the asset simultaneously, or to settle on a net basis, all related financial effects are offset.

# Derecognition of financial assets and liabilities

The Scheme derecognises an asset when the contractual rights to the asset expire, where there is a transfer of the contractual rights that comprise the asset, or the Scheme retains the contractual rights of the asset but assumes a corresponding liability to transfer these contractual rights to another party and consequently transfers substantially all the risks and benefits associated with the asset.

Where the Scheme retains substantially all the risks and benefits of ownership of the financial asset, the Scheme continues to recognise the financial asset.

The Scheme derecognises a financial liability when the contractual obligations are discharged, cancelled or expire.



(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 1.3 Financial assets: initial and subsequent measurement

Financial instruments are recognised when the Scheme becomes a party to the contractual provisions of the instrument.

Non-derivative financial instruments are recognised initially at fair value plus any directly attributable transaction costs, for instruments not at fair value through profit or loss.

#### Available-for-sale investments

Subsequent to initial recognition, available-for-sale investments are carried at fair value. Gains and losses arising from changes in the fair value of the available-for-sale investments are taken directly to the available-for-sale reserve. Once an available-for-sale investment is sold, the related cumulative fair value gain or loss is transferred out of the reserve to profit or loss.

#### Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except for maturities greater than 12 months after the reporting date. These are classified as non-current assets. The Scheme's loans and receivables comprise trade and other receivables and cash and cash equivalents in the statement of financial position.

Subsequently loans and receivables are measured at amortised cost using the effective interest method, less impairment. An impairment of trade receivables is established when there is objective evidence that the Scheme will not be able to collect all amounts due according to the original terms of the receivables. Receivables arising from healthcare insurance contracts with members are also classified in this category and are reviewed for impairment as part of the impairment review conducted per note 1.5.

#### Insurance receivables

Insurance receivables are carried at cost less impairment losses. Impairment losses on insurance receivables are recognised and determined in a similar manner to impairment losses on financial assets carried at amortised cost (refer to note 1.5).

## Cash and cash equivalents

In the statement of cash flows, cash and cash equivalents comprise:

- · Money on call and short notice deposits; and
- · Balances with banks.

Cash and cash equivalents include items held for the purpose of meeting short-term cash commitments. Cash and cash equivalents have a maturity of less than three months and an insignificant risk of changes in fair value. Subsequently, cash and cash equivalents are measured at amortised cost which approximates fair value.



(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 1.4 Financial liabilities

A financial liability is any liability that is a contractual obligation to deliver cash or another financial asset to another entity. Financial liabilities include trade payables. The Scheme is not permitted to borrow in terms of Section 35(6)(c) of the Medical Schemes Act, of South Africa. The Scheme therefore has no long-term financial liabilities.

#### Trade and other payables

Trade and other payables are measured initially at fair value plus directly attributable transaction costs and subsequently measured at amortised cost using the effective interest method.

#### Insurance payables

Insurance payables are measured initially at fair value (which approximates cost) and subsequently measured at amortised cost using the effective interest method.

Members' medical savings accounts: monies managed by the Scheme on behalf of its members

The members' medical savings account, which is managed by the Scheme on behalf of its members, represents savings contributions (which are a deposit component of the insurance contracts) and accrued interest thereon, net of any savings claims paid on behalf of members in terms of the Scheme's registered rules.

The deposit component of the insurance contracts has been unbundled, since the Scheme can measure the deposit component separately. The insurance component is recognised as an insurance liability.

Unspent savings at the year-end are carried forward to meet future expenses for which the members are responsible. In terms of the Medical Schemes Act, 131 of 1998, as amended, balances standing to the credit of members are refundable only in terms of Regulation 10 of the Act.

Advances on savings contributions are funded by the Scheme's funds, and the risk of impairment is carried by the Scheme.

From 1 January 2017 the Scheme discontinued the MSA component of the benefit option. MSA balances owing to members are being refunded accordingly. The Scheme is attempting to refund all unpaid balances with assistance from the

Interest paid on members' medical savings accounts

For 2017 the interest paid on members' medical savings accounts is recognised in profit or loss using the effective interest method. No interest was paid on members' savings accounts in the current year.



(Registration no. 1526)

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 1.5 Impairment of financial assets

Financial assets carried at amortised cost

The Scheme assesses at each reporting date whether there is objective evidence that a financial asset is impaired. A financial asset, or group of financial assets, is impaired and impairment losses are incurred if, and only if, there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a "loss event") and that the loss event (or events) has an adverse impact on the estimated future cash flows of the financial asset that can be reliably estimated.

The Scheme first assesses whether objective evidence of impairment exists, individually for financial assets that are individually significant, such as service provider debtors. In the case of assets which are not individually significant, such as contribution debtors, financial assets are grouped on the basis of similar credit characteristics, such as asset type and past-due status. These characteristics are used in the estimation of future cash flows recoverable.

If there is objective evidence that an impairment loss on a financial asset has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows discounted at the financial asset's original effective interest rate. The carrying amount of the asset is reduced and the amount of the loss is recognised through profit or loss.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed by adjusting the allowance account. The amount of the reversal is recognised in profit or loss.

#### 1.6 Outstanding risk claims provision

Risk claims outstanding comprise provisions for the Scheme's estimate of the ultimate cost of settling all risk claims incurred but not yet reported (IBNR) at the reporting date. Risk claims outstanding are determined as accurately as possible based on a number of factors, which include previous experience in claims patterns, claims settlement patterns, changes in the nature and number of members according to gender and age, trends in claims frequency, changes in the claims processing cycle, and variations in the nature and average cost incurred per claim.

Estimated co-payments and payments from medical savings accounts (MSA) are deducted in calculating the outstanding risk claims provision.

Claims handling expenses are not separately accounted for as this service is provided by the Administrator and a fixed fee is paid for the full administration service including claims handling. No provision for claims handling expenses is required as the Scheme has no further liability to the Administrator at year end.

The Scheme does not discount its provision for outstanding risk claims since the effect of the time value of money is not considered material.

(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 1.7 Member insurance contracts

Contracts under which the Scheme accepts significant insurance risk from another party (the member and his/her registered dependants) by agreeing to compensate the member or other beneficiary if a specified uncertain future event (the insured event) adversely affects the member or other beneficiary, are classified as insurance contracts.

The contracts issued compensate the Scheme's members for healthcare expenses incurred and are detailed in note 21.

#### 1.8 Risk contribution income

Gross contributions comprise of risk contributions and medical savings account (MSA) contributions.

As of 1 January 2017 gross contributions comprised only of risk contributions.

Risk contributions on member insurance contracts are accounted for monthly when their collection in terms of the insurance contract is reasonably assured. Risk contributions are earned from the date of attachment of insurance risk, over the indemnity period on a straight-line basis and are recognised as revenue.

#### 1.9 Relevant healthcare expenditure

Relevant healthcare expenditure consists of net claims incurred, managed care fees and net income or expense from risk transfer arrangements.

#### 1.9.1 Risk claims incurred

Gross claims incurred comprise the total estimated cost of all claims arising from healthcare events that have occurred in the year and for which the Scheme is responsible, whether or not reported by the end of the year.

Net risk claims incurred (net of claims from members' medical savings accounts, recoveries from members for co-payments, recoveries from third parties (e.g. Motor Vehicle Accident and fraud recoveries) and discounts received from service providers) comprise:

- Claims submitted and accrued for services rendered during the year;
- Payments under provider contracts (managed care) for services rendered to members;
- · Over or under provisions relating to prior year claims;
- · Claims incurred but not yet reported; and
- · Claims settled in terms of risk transfer arrangements.

Anticipated recoveries under risk transfer arrangements are disclosed separately as assets and are assessed in a manner similar to the assessment of the outstanding claims provision and claims reported not yet paid.

#### 1.9.2 Managed care: management services fees

Managed care: management services fees comprise amounts paid or payable to a third party for managing the utilisation, costs and quality of healthcare services to the members of the Scheme. Managed care: management services fees are expensed as incurred.

(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 1.9.3 Risk transfer arrangements

Risk transfer arrangements are contractual arrangements whereby a third party undertakes to indemnify the Scheme against all or part of the loss that the Scheme may incur as a result of carrying on the business of a medical scheme. Risk transfer arrangements do not reduce the Scheme's primary obligations to its members and their dependants, but the arrangements only decrease the loss the Scheme may incur as a result of carrying on the business of a medical scheme.

Risk transfer premiums are recognised as an expense over the indemnity period on a straight-line basis.

Risk transfer claims and benefits reimbursed are presented in profit or loss and in the statement of financial position on a gross basis. Only contracts that give rise to a significant transfer of insurance risk are accounted for as an insurance contract. Amounts recoverable under such contracts are recognised in the same year as the related claim.

Assets relating to risk transfer arrangements include balances due under risk transfer arrangements for outstanding claims provisions and claims reported not yet paid. Amounts recoverable under risk transfer arrangements are estimated in a manner consistent with the outstanding claims provision, claims reported not yet paid and settled claims associated with the risk transfer arrangement.

Amounts recoverable under risk transfer arrangements are assessed for impairment at each reporting date. These assets are deemed impaired if there is objective evidence, as a result of an event that occurred after its initial recognition, that the Scheme may not recover all amounts due. The Scheme gathers the objective evidence that a risk transfer arrangement asset is impaired using the same process adopted for financial assets held at amortised cost. These processes are described in note 1.5.

#### 1.10 Liability adequacy test

At the reporting date, liability adequacy tests are performed to ensure the adequacy of the member insurance contract liability.

Liabilities for insurance contracts are tested for adequacy by discounting current estimates of all future cash flows and comparing this amount to the carrying amount of the liabilities net of any related assets. Where a shortfall is identified, an additional provision is made and charged to profit or loss.

#### 1.11 Investment income

Investment income comprises of dividends, interest income and realised gains or losses on the disposal of investments.

Interest income is recognised using the effective interest method.

Dividend income from investments is recognised when the right to receive payment is established.

#### 1.12 Unallocated funds

Unallocated funds arise on the receipt of unidentified deposits in favour of the Scheme.

Unallocated funds older than three years have legally prescribed and are included under other income in profit or loss.

#### 1.13 Income tax

In terms of section 10(1)(d) of the Income Tax Act, No 58 of 1962, as amended, receipts and accruals of a benefit fund are exempt from normal tax. A medical scheme is included in the definition of a benefit fund and consequently the Scheme is exempt from income tax.

(Registration no. 1526)

2.

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

	2018 R	2017 R
AVAILABLE-FOR-SALE INVESTMENTS		
Fair value at the beginning of the year	110,037,922	76,584,614
Additions	46,480,886	25,941,752
Unrealised (loss) / gain on revaluation of available-for-sale		
investments	(6,225,842)	7,843,860
Realised gain on disposal of available-for-sale	200 - 20 LONGO	
investments	5,231,520	146,854
Investment management fees	(690,142)	(479,158)
Disposals	(26,891,508)	S=
Fair value at the end of the year	127,942,836	110,037,922
Non-current	127,942,836	110,037,922
	127,942,836	110,037,922
The investments included above represent investments in:		
Segregated portfolio	25,894,672	13,165,479
Linked insurance policies	102,048,164	96,872,443
	127,942,836	110,037,922

Available-for-sale investments are classified as non-current assets, unless they are expected to be realised within twelve months of the reporting date or unless they will need to be realised to raise operating capital.

# 3. TRADE AND OTHER RECEIVABLES

Insurance receivables Contributions outstanding Amounts recoverable from members and suppliers	655,002 201,007	26,875 844,164
Amounts due Impairment losses	4,936,849 (4,735,842)	3,733,341 (2,889,177)
Total receivables arising from insurance contracts	856,009	871,039
Loans and receivables Interest receivable Sundry accounts receivable	303,035 2,619,552	263,830 2,538,683
Total loans and receivables	2,922,587	2,802,513
Total trade and other receivables	3,778,596	3,673,552

At 31 December 2018 the carrying amounts of trade and other receivables approximate their fair values due to the short-term maturities of these assets.

(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

		2018 R	2017 R
4.	CASH AND CASH EQUIVALENTS		
4.1	CURRENT, SHORT TERM DEPOSITS AND MONEY MARK	ET ACCOUNTS	
	Current accounts Short-term deposits and money market accounts	10,926,204 40,100,549	1,973.375 40,418,943
		51,026,753	42,392,318
	The weighted average interest rate on cash and cash equivalents was	7.31% (2017: 7.22%).	
4.2	PERSONAL MEDICAL SAVINGS ACCOUNT		
	Current accounts	<b>-</b> 3	9,408
			9,408
	Total cash and cash equivalents per statement of financial		
	position	51,026,753	42,401,726

There were no MSA funds in 2018 and the effective interest rate on the MSA account for 2017 was 6.37%

On 6 June 2017, the Constitutional Court ruled on an appeal by Genesis Medical Scheme, setting aside a judgment of the Supreme Court of Appeal on the basis that no trust relationship is automatically created by the Medical Schemes Act 131 of 1998 or the Financial Institutions (Protection of Assets) Act 28 of 2001, and that personal medical savings' account funds do not need to be held or administered separately or differently from any other assets and liabilities of the scheme, and that the scheme is the right holder of the funds, unless a trust relationship is deliberately constituted. The board of trustees considered and concluded that no trust relationship had been constituted between the Scheme and its members insofar as the personal medical savings account funds are concerned. This resulted in a decision by the Scheme to no longer hold the personal medical savings account funds separately.

At 31 December 2018, the carrying amounts of cash and cash equivalents approximate their fair values.

## 5. OUTSTANDING RISK CLAIMS PROVISION

Outstanding risk claims provision - not covered by risk transfer arrangements	4,000,000	3,000,000
Analysis of movement in outstanding risk claims		
Balance at beginning of year Payments in respect of prior year	3,000,000 (2,879,435)	1,700,000 (1,831,635)
Over / (under) provision in respect of prior year	120,565	(131,635)
Adjustment for current year	3,879,435	3,131,635
Balance at end of year	4,000,000	3,000,000
Analysis of outstanding risk claims provision		
Estimated gross claims	4,000,000	3,000,000
Balance at end of year	4,000,000	3,000,000

The Scheme's rules provide that risk claims may only be paid if the Scheme is notified of the risk claim and documentation is submitted within 4 months of the date of rendering the healthcare service.

(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 5. OUTSTANDING RISK CLAIMS PROVISION (continued)

The outstanding risk claims provision is an estimate of the proportion of the risk claims liability incurred in the current financial year that is expected to be reported and paid only after the reporting date. The cost of outstanding risk claims is estimated using an incurred but not reported (IBNR) analysis of data methodology. These methods extrapolate the development of paid and incurred claims and ultimate claims numbers for each benefit year based on observed development of earlier years and expected loss ratios. Runoff tables are used in situations where it takes time after the treatment date until the full extent of the claims to be paid is known. It is assumed that payments will emerge in a similar way in each service month. The proportional increase in the known cumulative payments from one development month to the next can then be used to calculate payments for future development months.

#### Process used to determine the assumptions

The process used to determine the assumptions is intended to result in neutral estimates of the most likely or expected outcome. The sources of data used as inputs for the assumptions are internal, using detailed studies that are carried out annually. There is more emphasis on current trends, and where in early years there is insufficient information to make a reliable best estimate of claims development, prudent assumptions are used.

This is done via a sophisticated multi-simulation actuarial model which incorporates updated demographic and claims data. The outstanding risk claims provision is calculated as the difference between the risk claims projected for the period less the risk claims paid up to the end of that period. This process is done on a monthly basis and regularly reconciled with the actual experience.

#### Assumptions

The assumptions that have the greatest effect on the measurement of the outstanding risk claims provision are the expected claims ratios for the most recent benefit years for the In-hospital, Chronic and Above Threshold categories of claims. These are used for assessing the outstanding risk claims provisions for the 2018 and 2017 benefit years.

The assumptions used in estimating the risk claims incurred for the Scheme are as follows:

At year-end, the process used to calculate the provision for outstanding claims includes the evaluation of the claims paid during the first two months subsequent to year-end in respect of 2018 treatment claims as well as the determination of key variables and assumptions most likely to result in a reliable estimate of the outstanding claims provision.

The most significant key variables and assumptions used in determining the outstanding claims provision are:

- · the previous experience in claims processing patterns;
- · average claims paid in the run-off period from March each year based on historical data.

#### Sensitivity analysis

An analysis of sensitivity around various scenarios for the general medical insurance business provides and indication of the adequacy of the provision. As opposed to claims for 2018 that have already been paid, the claims for 2019 estimated to be paid (or reopened) in future payment months are still subject to uncertainty. This quantity forms a useful basis for a sensitivity analysis in note 22.

(Registration no. 1526)

6.

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

	2018 R	2017 R
PERSONAL MEDICAL SAVINGS ACCOUNT LIABILITY		
Balance on savings account liability at the beginning of the year	216,626	1,176,520
Add:	(100 150)	
- Prior year adjustment	(108,152)	<b>11</b>
- Transfers received from other medical schemes	-	16,745
- Interest received on personal medical savings account (note 15)		37,776
	108,474	1,231,041
Less:		
- Claims paid to or on behalf of members (note 9)	(320)	(60,685)
- Refunds		(952,614)
- Bank charges and investment management fees incurred	(326)	(1,116)
Balance on savings account liability at the end of the year	107,828	216,626
Paramon or 2000 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 -		

The medical savings accounts contain a demand feature. In terms of Regulation 10 of the Medical Schemes Act, of South Africa, any credit balance on a member's personal medical savings account must be taken as a cash benefit when the member terminates his or her membership of the Scheme or benefit option, and enrols in another medical scheme without a personal medical savings account or does not enrol in another medical scheme.

The carrying amount of the medical savings accounts approximates their fair values, since it is payable on demand. The amounts were not discounted due to the demand feature.

The mismatch between the medical savings account liability and the related funds relates to timing differences. These timing differences are typically cleared within a one month period.

The investment of medical savings account monies managed by the Scheme on behalf of its members has been separately disclosed in note 4.

# 7. TRADE AND OTHER PAYABLES

Insurance liabilities		
Member and supplier liability - stale cheques	11,090	40,203
Member and supplier liability - unpresented cheques	29,796	31,843
Reported claims not yet paid	1,469,123	1,687,745
Amounts due to members	420,591	413,849
Amounts due to suppliers	1,048,532	1,273,896
Total liabilities arising from insurance contracts	1,510,009	1,759,791
Other liabilities		3
Amounts owing to Administrator (note 20)	993,311	1,440,222
Unallocated receipts	12,909	12,153
Accruals	435,114	343,150
Total	1,441,334	1,795,525
Total trade and other payables	2,951,343	3,555,316

At 31 December 2018 the carrying amounts of other liabilities approximate their fair values due to the short-term maturities of these liabilities.

(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

		2018	2017
		R	R
8.	RISK CONTRIBUTION INCOME		
	Gross contributions per registered rules	172,756,552	155,624,921
	Net contribution income	172,756,552	155,624,921

<sup>\*</sup> The savings contributions are received by the Scheme in terms of Regulation 10(1) and the Scheme's registered rules and held on behalf of its members. Refer to note 6 to the financial statements for more detail on how these monies were utilised.

# 9. RISK CLAIMS INCURRED

Current year claims Claims not covered by risk transfer arrangements Claims covered by risk transfer arrangements	137,150,184 136,046,110 1,104,074	121,520,602 120,672,699 847,903
Movement in outstanding claims provision  Over / (under) provision in prior year (note 5)  Adjustment for current year	1,000,000 120,565 879,435	1,300,000 (131,635) 1,431,635
	138,150,184	122,820,602
Less: Claims paid from members' savings accounts *	(320)	(60,685)
Risk claims incurred	138.149.864	122,759,917

<sup>\*</sup> Claims are paid on behalf of members from their personal medical savings accounts in terms of Regulation 10(3) and the Scheme's registered benefits. Refer to note 6 to the financial statements for a breakdown of the movement in these balances.

# 10. CLAIMS RECOVERIES FROM THIRD PARTIES

Motor Vehicle Accident recoveries	98,656	2,073,943
Hospital discounts	125,973	· ·
Forensic recoveries	1,825,627	2,100,692
	2,050,256	4,174,635



(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

2018	2017
R	R

# 11. NET INCOME ON RISK TRANSFER ARRANGEMENT

The Scheme had the following risk transfer arrangement transactions during the year:

Capitation fees paid	(272,914)	(275,934)
Recoveries under risk transfer arrangements	1,104,074	847,903
	831,160	571,969

# **Netcare 911 Proprietary Limited**

Netcare 911 Proprietary Limited provided emergency medical advice, emergency medical response and transportation to the members of the Scheme. The contract is renewed annually unless either party gives 60 days written notice of termination of the agreement.

- Claims experience and resulting calculations on ground ambulance and flight claims were supplied by Netcare 911 Proprietary Limited.
- Netcare 911 Proprietary Limited applied estimated non-capitated fee information to these utilisation statistics, to determine the estimated cost to the Scheme. These claims included data on claims payments made in 2018 for 2017, claim payments for 2018 in respect of 2018 claims and payments incurred but not yet reported.

# 12. MANAGED CARE: MANAGEMENT SERVICES

Pharmaceutical benefit management	367,133	327,358
Specialist, hospital referrals and pre-authorisations	1,137,532	1,015,826
Disease management	1,174,495	1,048,594
Network management	990,928	885,079
	3,670,088	3,276,857



(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2018

		2018 R	2017 R
13.	OTHER OPERATING EXPENSES		
	Association fees Audit fees Audit services - current year Audit services - prior year under provision Bank charges Board of Healthcare Funders Council for Medical Schemes - rule amendments Fidelity guarantee and professional indemnity insurance premium Motor Vehicle Accident administration and legal fees Printing costs Training costs Trustee reimbursements (note 20)	118,759 255,579 255,579 - 69,363 6,791 11,660 20,025 35,905 126,327 28,500 6,058	92,385 257,902 254,106 3,796 66,567 5,273 5,885 20,025 4,850 154,803 - 2,570
14.	NET IMPAIRMENT ON HEALTHCARE RECEIVABLES Insurance receivables		
	Members' and service providers' portions not recoverable Increase in impairment Written off	1,945,106 1,846,666 98,440 1,945,106	1,218,467 734,942 483,525 1,218,467
15.	INVESTMENT INCOME		an
	Interest on cash and cash equivalents Income from investments Realised gains on disposal of available-for-sale investments Interest received on personal medical savings account (note 6)	180,390 4,231,294 5,231,520 - 9,643,204	190,046 3,341,226 146,854 37,776 3,715,902
16.	OTHER OPERATING INCOME		
	Prescribed debt written back Stale cheques (prescribed) / written back	38,708 (9,627) 29,081	2,746 9,627 12,373

(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

# 17. CASH FLOWS FROM OPERATIONS BEFORE WORKING CAPITAL CHANGES

Net surplus for the year	32,573,598	28,849,270
Adjustments for:		
- Movement in provision for impairment losses	1,846,666	734,942
- Income from investments	(4,411,684)	(3,569,049)
- Realised gains on disposal of available-for-sale investments	(5,231,520)	(146,854)
- Interest paid		37,776
Cash flows from operations before working capital changes	24,777,060	25,906,085

#### 18. COMMITMENTS AND OTHER CONTINGENT LIABILITIES

The Scheme does not have any commitments or contingent liabilities outstanding at 31 December 2018.

#### 19. EVENTS AFTER THE REPORTING DATE

There have been no events that occurred subsequent to the end of the accounting period that affect the financial statements and that the Trustees consider should be reported.

#### 20. RELATED PARTY TRANSACTIONS

The Scheme is controlled by the Board of Trustees who are appointed by the employers and elected by the members of the Scheme.

Parties with significant influence over the Scheme:

Administrator and managed care organisation

Discovery Health Proprietary Limited has significant influence over the Scheme as Discovery Health Proprietary Limited participates in the Scheme's financial and operating policy decisions, but does not control the Scheme. Discovery Health Proprietary Limited provides administration and managed care services.

Discovery Third Party Recovery Services

The Scheme has contracted Discovery Third Party Recovery Services Proprietary Limited (DTPRS), a wholly owned subsidiary of Discovery Health Proprietary Limited, to manage the indentification and collection of third party recoveries from the Road Accident Fund.

Key management personnel

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Scheme. Key management personnel include the Board of Trustees and the Principal Officer.

Close family members include family members of the Board of Trustees and Principal Officer.

BMW Financial Services (SA) Proprietary Limited and BMW (SA) Proprietary Limited

BMW Financial Services (SA) Proprietary Limited and BMW (SA) Proprietary Limited are the two employer companies, both these companies are considered related parties. Both entities participate in the Scheme's financial and operating policy decisions, but do not control the Scheme.

(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

# 20. RELATED PARTY TRANSACTIONS (continued)

# Transactions with key management personnel

The following table provides the total amount of transactions, which have been entered into with related parties for the relevant financial year.

the relevant financial year.	2018 R	2017 R
Key management personnel		
Contributions and claims (Trustees and their beneficiaries)		
- Statement of comprehensive income		
Gross contributions received	910,352	692,799
Gross claims incurred	(652,616)	(836,884)
Interest credited to medical savings account balances	-	(98)
Trustee reimbursements		
- Statement of comprehensive income		
Trustee training	(28,500)	
Travel reimbursements	(6,058)	(2,570)

The terms and conditions of the related party transactions were as follows:

Transaction	Nature of transactions and terms and conditions thereof
Contributions received	This constitutes the contributions paid by the related parties as members of the Scheme in their individual capacity. All contributions were on the same terms as those applicable to other members.
Claims incurred	This constitutes amounts claimed by the related parties in their individual capacity as members of the Scheme. All claims were paid out in terms of the rules of the Scheme, as applicable to other members.



(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 20. RELATED PARTY TRANSACTIONS (continued)

	2018 R	2017 R
Transactions with parties that have significant influence over the Schen	ne	
Discovery Health Proprietary Limited - administrator Statement of comprehensive income Administration fees paid	(7,602,488)	(6,788,446)
Discovery Health Proprietary Limited - managed care organisation Statement of comprehensive income Managed care fees paid	(3,670,088)	(3,276,857)
Statement of financial position Balance due to Discovery Health Proprietary Limited (note 7)	993,311	1,440,222
Discovery Third Party Recovery Services Proprietary Limited Statement of comprehensive income Road Accident Fund recoveries	<u>.</u>	2,030,496

The terms and conditions of the transactions with entities with significant influence over the Scheme were as follows:

Administration and managed care management service agreements

The administration and managed care management service agreements are in terms of the rules of the Scheme and in accordance with instructions given by the Board of Trustees. The agreements are automatically renewed each year unless notification of termination is received or following the cancellation of the Administrator's accreditation or the issue of a lawful directive to this effect by the Council for Medical Schemes in terms of the Medical Schemes Act, of South Africa. The Scheme and the Administrator/Managed Healthcare Organisation shall be entitled to terminate the agreement by giving notice in writing of not less than 90 days and not more than 180 days. The outstanding balance bears no interest and is due within 7 days.

#### BMW Financial Services (SA) Proprietary Limited and BMW (SA) Proprietary Limited

Gross contributions	172,756,552	155,624,921
Statement of financial position (note 3)	655,002	26,875
Risk contribution debtors	033,002	20,073



(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

# 21. INSURANCE RISK MANAGEMENT REPORT

# Nature and extent of risks arising from insurance contracts

The primary insurance activity carried out by the Scheme indemnifies covered members and their dependants against the risk of loss arising as a result of the occurrence of a health event (i.e. an event relating to the health of the Scheme member and his or her registered dependants). As such, the Scheme is exposed to the uncertainty surrounding the timing and severity of claims under the contract. Insurance events are, by nature, random and the actual number and size of events during any one year may vary.

This section summarises these risks and the way they are managed.

#### Insurance risk

For a portfolio of insurance contracts where the theory of probability is applied to pricing and provisioning, the principal risk that the Scheme faces under its insurance contracts is that the actual claim payments exceed the carrying amount of the insurance liabilities. This could occur because the frequency and/or severity of claims are greater than estimated.

Factors that aggravate insurance risk include changes in membership distribution and major unanticipated demographic movements, adverse experience regarding the cost of prescribed minimum benefits and unusually adverse experience due to seasonal patterns.

# Risk management objectives and policies for mitigating insurance risk

The Scheme's annual budget is prepared under strict actuarial supervision which determines the contributions against claims projections, taking the statutory solvency requirements into account. The performance against the budget is closely monitored by the Board of Trustees and appointed sub-committees. Should any deviations occur, they are investigated with the necessary interventions implemented.

The methods employed by the Scheme to monitor and manage its insurance risk, inherent in the medical scheme environment, include the following:

- · The Board of Trustees monitor and review all financial and operational performance on a monthly basis;
- · All claims and demographic movements are monitored on a monthly basis via a multi-simulation actuarial model;
- · Actuarial projections of the Scheme's year-end financial position are done monthly;
- The Scheme also applies a number of managed care programmes to monitor and manage the appropriateness, cost and quality of the healthcare services provided to the beneficiaries of the Scheme; and
- The need for re-insurance is considered on an ongoing basis within the existing regulatory environment.



(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 21. INSURANCE RISK MANAGEMENT REPORT (continued)

#### Insurance risk - description of benefit option

The Scheme offers members one benefit option. The types of benefits offered by the Scheme in return for monthly contributions are indicated below:

Prescribed Minimum Benefits (PMBs)

This benefit covers the benefits contemplated in section 29(1)(o) of the Act and consists of the provision of the diagnosis, treatment and care costs of the diagnosis and treatment pairs listed in Annexure A of the Regulations, subject to any limitations specified therein and any emergency medical condition.

The Scheme applies guidelines and protocols for appropriate clinical management under Designated Service Provider (DSP) agreements.

Major Medical Expenses (insured benefits)

Hospital Benefit

The hospital benefit covers medical expenses incurred if members are admitted to hospital and the Scheme has authorised the treatment.

Clinical protocols and provider contracting are applied to pre-authorisations and the management of the benefit.

The Administrator negotiates hospital tariffs annually on behalf of the Scheme to allow for benefit of scale.

Chronic Illness Benefit (CIB)

The chronic illness benefit covers approved medication for up to 48 listed conditions. These are the 27 Prescribed Minimum Benefit chronic conditions and other non-prescribed chronic conditions.

This benefit and approval are managed by an appointed accredited Managed Care Organisation for drug utilisation, medicine management and adherence to compliance with regard to the Prescribed Minimum Benefit conditions.

Other services (insured procedure benefits)

These services provide cover for non-hospital expenses, subject to prior approval from the Scheme, which is managed and monitored by an appointed clinical committee.

Personal Medical Savings Account

This benefit provides cover for out-of-hospital healthcare services, such as visits to a general practitioner. The savings plan facility assists members in managing cash flows for costs to be borne by them during the year.



(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 21. INSURANCE RISK MANAGEMENT REPORT (continued)

#### Hospital Benefit risk

Frequency and severity of claims

The frequency and severity of claims can be affected by several factors. The most significant factor is the admission rate which has a direct impact on the cost of claims.

A 2% increase or decrease in the admission rate is estimated to increase or decrease the Scheme's loss ratio by 1.41%. The introduction of new hospital technologies could also increase variability of claims. In some instances, the new technology has a beneficial impact on costs, whether in-hospital or consequent costs. In other instances the new technologies will increase costs.

The change in the admission rate is shown in the following table.

Plan type	2018 Admission	2017 Admission rate	% Increase/ (decrease)
BMW Employees Medical Aid Society	22%	22%	0.00%

Other factors that impact on hospital claims are shown below.

Key indicators	2018	2017	% Increase/ (decrease)
Length of stay	3.44 days	3.62 days	-4.97%
Average cost per event *	R 22,628	R 21,677	4.39%
Hospital cost per life per month *	R 416	R 396	5.05%

<sup>\*</sup> After adjusting for IBNR, case mix and excluding the cost of professionals attending in-hospital.

Initiatives used by the Scheme to manage the risk associated with admission rate include:

- The development of protocols around admissions, including funding protocols for various treatments and procedures;
- The "See Your Doctor First" initiative which requires members to see their doctor prior to an elective admission; and
- The amendment to the pre-authorisation length of stay benchmarks.

#### Chronic Illness Benefit (CIB) risk

Frequency and severity of claims

The main factors impacting the frequency and/or severity of chronic claims are the number of claimants and the cost per claimant. An increase in the number of claimants results in an increase in the frequency and/or severity of claims. Higher increases in claimants can be attributed to increases in the number of claimants at older ages. Increases in the number of items per claimant drives up the cost of chronic claims per claimant.

The mix between the various chronic conditions impacts the frequency and severity of claims. The following table shows the change in the chronic prevalence for key measures.

Measures	2018	2017	% Increase/ (decrease)
Cost per claimant	R 4,890	R 4,591	6.49%
Claimants per 1 000 lives	15	15	0.67%
Per life per month cost	R 74	R 69	7.23%

(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 21. INSURANCE RISK MANAGEMENT REPORT (continued)

#### Day-to-day benefit risk

Frequency and severity of claims

The risk to the Scheme is limited up to an annual limit per benefit per family via individualised medical savings accounts, as prescribed by the rules of the Scheme.

#### Concentration of insurance risk

The following table summarises the concentration of insurance risk, with reference to the carrying amount of the insurance claims incurred (net of adjustments per beneficiary) for service years 2018 and 2017, by age group and in relation to the type of risk cover/benefits provided.

Claims incurred for 2018 service year per beneficiary

Age grouping (in years)	Avg number of beneficiaries	In-hospital R	Chronic R	Day-to-day R	Total R
< 26	3,513	4,572	351	4,538	9,461
26 – 35	1,748	6,144	356	8,125	14,625
36 – 50	1,872	8,933	1,232	10,405	20,570
> 50	1,023	19,684	2,970	15,083	37,736

Claims incurred for 2017 service year per beneficiary

Age grouping (in years)	Avg number of beneficiaries	In-hospital R	Chronic R	Day-to-day R	Total R
< 26	3,307	3,760	294	4,067	8,121
26-35	1,566	7,323	312	7,910	15,545
36 - 50	1,930	7,999	1,138	9,228	18,365
> 50	1,100	14,852	2,512	12,279	29,643

Contracts with providers are negotiated by the Administrator on behalf of the Scheme to benefit from scale and ultimately the rates. Such contracts are reviewed annually.

# Risk transfer arrangements

The Scheme has a capitation agreement to cover specific risks. The Scheme has contracted with the Netcare 911 Proprietary Limited for emergency medical response.

## Risk in terms of risk transfer arrangements

According to the terms of the capitation agreement, the provider provides certain benefits to Scheme members, as and when required by the members. The Scheme does however remain liable to its members if the supplier should fail to meet its obligations.

(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 21. INSURANCE RISK MANAGEMENT REPORT (continued)

#### Claims development

Claims development tables are not presented as the uncertainty regarding the amount and timing of claim payments is typically resolved within one year and in the majority of cases within four months. At year end, a provision is made for those claims outstanding that are not yet reported at that date. Details regarding the subsequent development in respect thereof have been disclosed in note 5.

#### Outstanding risk claims provision

There are some sources of uncertainty that need to be considered in the estimate of the liability that the Scheme will ultimately pay for claims made under insurance contracts.

Process used to determine the assumptions

Refer to note 5.

Changes in assumptions and sensitivities to changes in key variables

The table below outlines the sensitivity of insured liability estimates to particular movements in assumptions used in the estimation process. It should be noted that this is a deterministic approach with no correlations between the key variables. For each sensitivity illustrated, all other assumptions have been left unchanged.

Where variables are considered to be immaterial, no impact has been assessed for insignificant changes to these variables. Particular variables may not be considered material at present. However, should the materiality level of an individual variable change, assessment of changes to that variable in the future may be required.

An analysis of the sensitivities around various scenarios for the general medical insurance business provides an indication of the adequacy of the Scheme's estimation process. The Scheme believes that the liability for claims reported in the statement of financial position is adequate. However, it recognises that the process of estimation is based upon certain variables and assumptions which could differ when claims arise.

The impact on the liability and reported profits caused by changes in key variables are as follows:

	Change in variable %	Increase in 2018	Increase in liability 2017 R
Risk claims incurred	10% increase in claims cost	400,000	300,000

The Scheme is most vulnerable to changes in membership distribution and changes in the underlying rate of inflation which drives a number of assumptions.

Sensitivity of the Scheme's profit or loss and reserves to changes in variables that have a material effect on

The Scheme's profitability, reserves and therefore solvency are most sensitive to changes in claims development patterns. Other assumptions that are considered include assumptions regarding utilisation trends, the impact of new technology and the expected demographic profile of the Scheme membership.

(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

# 22. FINANCIAL RISK MANAGEMENT REPORT

#### Overview

The Scheme is exposed to financial risk through its financial assets, financial liabilities and insurance liabilities. In particular, the key financial risk is that the proceeds from its financial assets may not be sufficient to fund the obligations arising from its insurance contracts. The most important components of this financial risk are market risk, credit risk and liquidity risk. The Scheme's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Scheme's statutory solvency requirement.

The Board of Trustees has overall responsibility for the establishment and oversight of the Scheme's risk management framework.

The Scheme manages these risks through various risk management processes. These processes have been developed to ensure that the long-term investment return on assets supporting the insurance liabilities is sufficient to fund members' reasonable benefit expectations.

An Audit and Risk Committee has been established by the Board of Trustees to assist in the implementation and monitoring of these risk management processes.

#### Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices, will affect the Scheme's income or the value of its holdings in financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return on risk.

#### Currency risk

All of the Scheme's benefits are denominated in South African Rands (ZAR) and therefore the Scheme does not have significant net currency risk.

#### Price risk

The Scheme is exposed to equity security price risk because of investments held by the Scheme. To manage its price risk arising from investments in equity securities, the Scheme diversifies its portfolio. Diversification of the portfolio is done by the relevant asset managers through the investments held in a segregated portfolio and linked insurance policies.

The Scheme continues to pursue a more growth-orientated investment strategy, in accordance with the Act and Regulations thereto.

(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

# 22. FINANCIAL RISK MANAGEMENT REPORT (continued)

#### Interest rate risk

The Scheme is exposed to interest rate risk as it places funds at both fixed and floating interest rates. The risk is managed by maintaining an appropriate mix between fixed and floating rate investments within the Scheme's cash and cash equivalents.

The table below summarises the Scheme's exposure to interest rate risks. Included in the table are the Scheme's cash and cash equivalents, categorised by the earlier of contractual repricing or maturity dates.

	Up to 1 month	1 to 3 months	3 and more months	Total
As at 31 December 2018	R	R	R	R
Cash and cash equivalents	51,026,753	-	74	51,026,753
Total	51,026,753	_	-	51,026,753

	Up to 1 month	1 to 3 months	3 and more months	Total
As at 31 December 2017	R	R	R	R
Cash and cash equivalents	42,392,318	-		42,392,318
Total	42,392,318	40,418,943	-	82,811,262

The following table below summarises the effective interest rate for monetary financial instruments:

Current, short term deposits and money market accounts Personal medical savings account

2018	2017
7.29%	7.22%
-	6.37%

Sensitivity analysis for available-for-sale investments and cash and cash equivalents (excluding Personal members savings account)

Sensitivity analysis: Cash

#### Basis:

The sensitivity analysis determines different levels of the closing market value as compared to the actual closing market value based on different levels of interest (see table below). i.e. +1% suggests the closing market value could have been R65,638,081 if the interest had been higher by 1% during 2018 as compared to the actual interest rate. A one percent increase in the interest at the reporting date would have increased cash by R606,111 (2017 an increase of R608,708). An equal change in the opposite direction would have decreased cash by R606,111 (2017 a decrease of R608,708).

% Change	Return of Index	Adjusted Closing Value R	Difference R
2.00%	9.29%	66,244,207	1,212,223
1.00%	8.29%	65,638,081	606,111
0.00%	7.29%	65,031,955	12
(1%)			(606,111)
(2%)	5.29%	63,819,703	(1,212,223)



(Registration no. 1526)

## NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

## 22. FINANCIAL RISK MANAGEMENT REPORT (continued)

Sensitivity analysis: Bonds

#### Basis

The sensitivity analysis determines different levels of the closing market value as compared to the actual closing market value based on different levels of investment performance (see table below). i.e. +1% suggests the closing market value could have been R55,238,955 if the investment performance had been higher by 1% during 2018 as compared to the market investment performance. A one percent increase in the investment return at the reporting date would have increased bonds by R508,247 (2017 an increase of R351,149). An equal change in the opposite direction would have decreased bonds by R508,247 (2017 a decrease of R351,149).

% Change	Return of Index	Adjusted Closing Value R	Difference R
2.00%	9.69%	55,747,202	1,016.493
1.00%	8.69%	55,238,955	508,247
0.00%	7.69%	54,730,708	) <u>m</u> 2
-1.00%	6.69%	54,222,462	(508,247)
-2.00%	5.69%	53,714,215	(1.016.493)

Sensitivity analysis: Equity

#### Basis:

The sensitivity analysis determines different levels of the closing market value as compared to the actual closing market value based on different levels of investment performance (see table below). i.e. +2% suggests the closing market value could have been R60,501,468 if the investment performance had been higher by 2% during 2018 as compared to the market investment performance.

All equity investments are listed on the JSE. A two percent increase in the investment return at the reporting date would have increased equity by R1,294,542 (2017 a increase of R798,491); an equal change in the opposite direction would have decreased equity by R1,294,542 (2017 a decrease of R798,491).

The change will have an impact on the revaluation reserve and/or the profit/loss depending on the investment type.

% Change	Return of Index	Adjusted Closing Value R	Difference R
4.00%	-4.53%	61,796,010	2,589,084
2.00%	-6.53%	60,501,468	1,294,542
0.00%	-8.53%	59,206,926	-
-2.00%	-10.53%	57,912,385	(1,294,542)
-4.00%	-12.53%	56,617,843	(2,589,084)



(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

# 22. FINANCIAL RISK MANAGEMENT REPORT (continued)

#### Credit rick

Credit risk is the risk of financial loss to the Scheme if a counterparty to a financial instrument fails to meet its contractual obligations.

The Scheme's principal financial assets are cash and cash equivalents, trade and other receivables and available-forsale investments. The Scheme's credit risk is primarily attributable to its trade and other receivables.

#### Trade and other receivables

Trade and other receivables comprises of insurance receivables and loans and receivables. The main components of insurance receivables are in respect of:

- · Receivables for contributions due from members; and
- Receivables for amounts recoverable from service providers and members in respect of claims debt.

The Scheme manages credit risk by:

- Actively pursuing all contributions after 3 days of becoming due, as required by S26(7) of the Medical Schemes Act, of South Africa;
- · Suspending benefits on members' accounts whose contributions have not been received for 30 days;
- Terminating benefits on members' accounts whose contributions have not been received for 60 days; and
- · Ageing and pursuing unpaid accounts on a monthly basis.

The Scheme establishes an allowance for impairment that represents its estimate of incurred losses in respect of trade and other receivables. The main components of this allowance are a specific loss component that relates to individually significant exposures, and a collective loss component established for groups of similar assets in respect of losses that have been incurred but not yet identified. The collective loss allowance is determined based on historical data of payment statistics for similar financial assets.

Details of the process to estimate the impairment provision are included in note 1.5.

#### Cash and cash equivalents

The Scheme has no significant concentration of credit risk. Cash transactions are limited to financial institutions with a high credit rating. The Scheme has a policy of limiting the amount of credit exposure to any one financial institution.

The table below shows the credit limit and balances of cash and cash equivalents held at 5 major counterparties at year end which is in compliance with Annexure B of the Regulations. The statutory credit limit is calculated as 35% of the aggregate fair value of liabilities and accumulated funds.

	201	2018		17
Counterparty	Credit limit R	Balance R	Credit limit R	Balance R
1.4	58,334,350	20,371,128	46,866,534	15,563,219
2	58,334,350	12,806,822	46,866,534	12,744,710
3	58,334,350	6,268,941	46,866,534	14,724,022
4	58,334,350	14,403,468	46,866,534	15,927,304
5	58,334,350	4,367,813	46,866,534	2,739,664

No credit limits were exceeded during the reporting period and the Trustees do not expect any losses from non-performance of these counterparties.

#### Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure.



(Registration no. 1526)

## NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 22. FINANCIAL RISK MANAGEMENT REPORT (continued)

#### Exposure to credit risk (continued)

#### Impairment

The ageing of insurance receivables at year end was:

	2018		2	017
	Gross R	Impairment R	Gross R	Impairment R
Not past due	727,282	<b>a</b>	97,577	
Past due, not impaired	128,727		772,338	-
Past due, impaired	4,735,842	(4,735,842)	2,889,177	(2,889,177)
	5,591,851	(4,735,842)	3,759,092	(2,889,177)

The movement in the allowance for impairment during the year was as follows:

The movement in the anomaloe for impartion during the	2018	2017
	R	R
Balance at the beginning of the year	(2,889,176)	(2,154,234)
Increase in impairment	(1,846,666)	(734,942)
Balance at the end of the year	(4,735,842)	(2,889,176)

Based on past experience, the Scheme believes that no allowance is necessary in respect of insurance receivables that are past due and outstanding for less than 60 days.

#### Available-for-sale investments

The Scheme limits its exposure to credit risk by investing in liquid securities and only with counterparties that have a high credit rating. The Trustees do not expect any counterparty to fail to meet its obligations. Annexure B to Regulation 30 to the Medical Schemes Act, of South Africa, prescribes the credit limits per institution which reduces the individual risk per institution. The utilisation of these limits are regularly monitored.

#### Credit quality of financial assets

The credit quality of financial assets that are neither past due nor impaired can be assessed by reference to external credit ratings (if available) or to historical information about counterparty default rates:

	2018 R	2017 R
Insurance receivables		
Counterparties without external credit ratings		
Contribution debtors	655,002	26,875
Member claims receivables	297,045	297,045
Provider claims receivables	475,962	475,962
	1,428,009	799,882



(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

# 22. FINANCIAL RISK MANAGEMENT REPORT (continued)

#### Contribution debtors

On analysing the credit quality of contribution debtors, the Scheme collected 100% of these amounts in January. This indicates a high credit quality rating of these debtors.

## Active member claims debtors

These debtors are members of the Scheme and therefore are expected to have a similar credit quality to the contribution debtors.

Countries with automater the automater	n (Mandula)	2018 R	2017 R
Counterparties with external credit rating	s (Moody's)		
Cash and cash equivalents			
Current accounts	Baa2	10,926,204	1,982,783
Nedbank Money Market	Baa2	13,779,419	23,519,899
Investec Money Market	Baa2	26,321,130	16,899,046
,		51,026,753	42,401,728
Available-for-sale investments  Segregated portfolio: Aluwani Capital Partners (Proprietary) Lim Huysamer Capital Investments Proprietary Mazi Asset Management (Proprietary) Lim	Limited	16,096,331 - 9,798,341	13,165,479
Linked insurance policy: Allan Gray Proprietary Limited Prudential Portfolio Managers (South Afric Coronation Fund Managers Sanlam Collective Investments (RF) Propri	ea) Life Limited	17,591,819 28,766,838 - 33,688,549	29,011,475 14,763,823 33,002,197
Prescient Management Company Proprieta	ry Limited	22,000,957	20,094,948
		127,942,836	110,037,923

## Asset allocation of Scheme (excluding Personal medical savings account trust funds)

Asset Class	2018	2017 R
	R	
Cash	65,031,955	65,447,455
Bonds	54,730,708	38,702,213
Equity	59,206,926	48,290,566
Total	178,969,589	152,440,235



(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

## 22. FINANCIAL RISK MANAGEMENT REPORT (continued)

#### Liquidity risk

Liquidity risk is the risk that the Scheme will not be able to meet its financial obligations as they fall due. The Scheme's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Scheme's reputation.

Approximately 99% of the Scheme's insurance liabilities are settled within four months after the claim was incurred and the remaining liability is settled within eight months.

A maturity analysis for financial liabilities, including insurance liabilities is provided below:

As at 31 December 2018	Total
Outstanding risk claims provision (note 5)	R 4,000,000
Members' savings accounts (note 6)	R 107,828
Trade and other payables (note 7)	R 2,951,343
As at 31 December 2017	Total
Outstanding risk claims provision (note 5)	R 3,000,000
Members' savings accounts (note 6)	R 216,626
Trade and other payables (note 7)	R 3,555,316

#### Legal risk

Legal risk is the risk that the Scheme will be exposed to contractual obligations which have not been provided for. At 31 December 2018 the Scheme did not consider there to be any significant concentration of legal risk that had not been provided for.

## Capital management

The Scheme is subject to the capital requirement imposed by Regulation 29(2) to the Medical Schemes Act, of South Africa, which requires a minimum solvency ratio of accumulated funds expressed as a percentage of gross contributions to be 25%.

The Scheme's objectives when managing capital are to maintain the requirements of the Medical Schemes Act, of South Africa, and to safeguard the Scheme's ability to continue as a going concern in order to provide benefits for its stakeholders.

The calculation of the regulatory capital requirement is set out below.

The calculation of the 18g mater, eaphine 19	2018 R	2017 R
Total members' funds per statement of financial position Less: Cumulative unrealised net gain on remeasurement to fair value of	175,689,014	149,341,258
investments	(12,300,016)	(18,525,858)
Accumulated funds per Regulation 29	163,388,998	130,815,399
Annualised gross contributions	172,756,552	155,624,921
Solvency margin  = Accumulated funds/annualised gross contribution income x 100	94.58%	84.06%
		0



(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

## 22. FINANCIAL RISK MANAGEMENT REPORT (continued)

#### Investment risk

The Scheme's Audit and Risk Committee invests excess funds in line with the Medical Schemes Act of South Africa.

The Scheme's investment objectives are to maximise the return on its investments on a long-term basis at acceptable risk, subject to any constraints imposed by legislation or the Trustees. The Scheme continues to diversify its investment portfolio by investing in a segregated portfolio and linked insurance policies.

Continuous monitoring takes place to ensure that appropriate assets are held where the Scheme's liabilities are dependent upon the performance of the investment portfolio and that a suitable match of assets exists for all liabilities.

#### Breakdown of investments

The assets of the portfolio, excluding Personal Medical Savings Account, must be invested in accordance with Annexure B of Regulation 30 to the Medical Schemes Act, of South Africa.

The investments for the purposes of the financial statements comprise of available-for-sale investments and cash and cash equivalents.

	2018	2017
	R	R
Available-for-sale investments are made up of the following:		
Segregated portfolio	25,894,672	13,165,479
Linked insurance policy	102,048,164	96,872,443
	127,942,836	110,037,922
Cash and cash equivalents are made up of the following:		
Current accounts	10,926,204	1,973,375
Money market instruments	40,100,549	40,418,945
	51,026,753	42,392,320



(Registration no. 1526)

# NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

# 22. FINANCIAL RISK MANAGEMENT REPORT (continued)

## Fair value estimation

The face values less any estimated credit adjustments for financial assets and liabilities with a maturity of less than one year are assumed to approximate their fair values.

Analysis of carrying amounts of financial assets and financial liabilities per category

The following table compares the fair value and carrying amounts of financial assets and liabilities per class of financial asset and financial liability. The carrying amount is the fair value.

	Available-for- sale investments	Loans and receivables/ (other financial liabilities)	Insurance receivables and payables	Total carrying amount
	R	R	R	R
31 December 2018				
Cash and cash equivalents	2	51,026,753	-	51,026,753
Trade and other receivables		2,922,587	856,009	3,778,596
Trade and other payables		(1,441,334)	(1,510,009)	(2,951,343)
Available-for-sale investments	127,942,836	-	-	127,942,836
Members' savings account liability	-	(107,828)	-	(107,828)
	127,942,836	52,400,178	(654,000)	179,689,014
31 December 2017				
Cash and cash equivalents		42,401,726		42,401,726
Trade and other receivables		2,802,513	871,039	
Trade and other payables	-	(1,795,525)	(1,759,791)	
Available-for-sale investments	110,037,922	5- - ()		110,037,922
Members' savings account liability		(216,626)	-	(216,626)
	110,037,922	43,192,088	(888,752	152,341,258

# 23. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

Critical accounting estimates and assumptions

The Scheme makes estimates and assumptions concerning the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The resulting accounting estimates will, by definition, rarely equal the related actual result. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are outlined below.

Outstanding risk claims provision

The critical estimates and judgements relating to the outstanding claims provision are set out under note 5.

Other risk transfer arrangements

The critical estimates and judgements relating to other risk transfer arrangements are set out under note 11.

Impairment of financial assets

The critical estimates and judgements relating to the impairment of assets are set out under note 1.5.



(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

# 23. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (continued)

Valuation of financial instruments

The Scheme's accounting policy on fair value measurements is discussed in accounting policy 1.3.

The Scheme measures fair values using the following fair value hierarchy that reflects the significance of the inputs used in making the measurements:

- Level 1: Quoted market price (unadjusted) in an active market for an identical instrument.
- Level 2: Valuation techniques based on observable inputs, either directly (i.e. prices) or indirectly (i.e. derived from prices). This category includes instruments valued using quoted market prices in active markets for similar instruments; quoted prices for identical or similar instruments in markets that are considered less than active; or other valuation techniques where all significant inputs are directly or indirectly observable from market data.
- Level 3: Valuation techniques using significant unobservable inputs. This category includes all instruments where
  the valuation technique includes inputs based on observable data and the unobservable inputs have a significant
  effect on the instrument's valuation. This category includes instruments that are valued based on quoted prices for
  similar instruments where significant unobservable adjustments or assumptions are required to reflect differences
  between the instruments.

All the Scheme's financial instruments at fair value (available-for-sale investments) are categorised as level 1.

#### 24. NON-COMPLIANCE MATTERS

# 24.1 Contributions not received within three days of them becoming due

In terms of Section 26(7) of the Medical Schemes Act, of South Africa ("the Act"), all subscriptions or contributions shall be paid directly to a medical scheme not later than three days after payment thereof becoming due.

Although the majority of contribution payments were made within the stipulated payment deadlines, there were a small number of instances where the Scheme received contributions after three days of becoming due. These contributions equate to 0.29% of the gross contributions billed and were received within the month of them becoming due. Such arrear payments are outside the agreed contribution collection agreements with paying parties and are actively addressed as and when they occur.

The procedures that the Scheme follows for collection of these arrear contributions are aligned with its credit risk management policies.

(Registration no. 1526)

#### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

#### 24. NON-COMPLIANCE MATTERS (continued)

# 24.2 Investment in participating employers and medical scheme administrators

At 31 December 2018, the Scheme indirectly held shares in MMI Holdings Limited amounting to R 321 992 (2017: R 93 280), Liberty Holdings Limited amounting to R 204 511 (2017: R 19 648) and Sanlam Limited amounting to R 871 164 (2017: R 381 256) and Discovery Holdings Limited amounting to R 2 479 214 in 2017.

Ordinarily this would be in contravention of Section 35(8) of the Act, which, inter alia, prohibits a medical scheme from investing any of its assets in an employer that participates in that scheme. However, as funds in these specific portfolios are structured at the sole discretion of the asset manager in a manner that maximizes the return on investment, and neither the Scheme nor these employers provide input into the structuring of the portfolio.

The Scheme has received exemption from the Council for Medical Schemes, from compliance this section of the Act.

#### 24.3 Claims payments in excess of 30 days

Member or provider claims should be settled within 30 days of submission. Instances were noted where settlements took more than 30 days.

Instances were identified where claims that were processed on time had not passed for payment within 30 days. These are isolated cases and thus do not have a material effect on the Scheme.

The error is not expected to re-occur as internal quality assurance checks have been implemented to ensure payments are released timeously.

(Registration no. 1526)

# REPORT OF THE BOARD OF TRUSTEES

The Board of Trustees hereby presents its report for the year ended 31 December 2018

## 1 DESCRIPTION OF THE SCHEME

## 1.1 Terms of registration

The BMW Employees Medical Aid Society is a not-for-profit restricted membership Scheme registered in terms of the Medical Schemes Act, of South Africa.

# 1.2 Benefit options within the BMW Employees Medical Aid Society

The Scheme offers one (1) benefit option.

## 1.3 Savings plan

From 1 January 2017 the Scheme discontinued the MSA component of the benefit option. MSA balances owing to members are being refunded accordingly. The Scheme is attempting to refund all unpaid balances with

(Registration no. 1526)

## REPORT OF THE BOARD OF TRUSTEES (continued)

#### 2 MANAGEMENT

#### 2.1 Board of Trustees in office during the year and at the date of this report was:

C Hector

Chairman - Employer Representative

N Moonia

Vice Chairman - Employer Representative - resigned 1 October 2018

D Radebe

Employer Representative

E Hlophane

Employee Representative Employee Representative

C Louw S Sohan

Employee Representative

K Madumo

Employee Representative

C McCrea-Phillips

**Employer Representative** 

S Hoon

Employer Representative

- appointed 10 June 2018

J Meiring JP Fegbeutel V Vatsha-Mahlaba Pensioner Alternative Representative Pensioner Member Representative Co-opted Employer Representative

Alternative Employer Representative

T Harakhchand

Alternative Employer Representative

- resigned 30 April 2018

K Kgomo J Selumane

Alternative Employer Representative

- appointed 1 October 2018

M Gounden G Shafee

Alternative Employer Representative Alternative Employer Representative

- appointed 1 October 2018

#### 2.2 Principal Officer

AR Kelbrick

#### 2.3 Registered office address and postal address

1 Discovery Place

PO Box

Sandton

Sandton

2146

2146

#### 2.4 Scheme administrator during the year

Discovery Health Proprietary Limited

1 Discovery Place

PO Box

Sandton 2146

Sandton 2146

(Registration no. 1526)

# REPORT OF THE BOARD OF TRUSTEES (continued)

# 4 REVIEW OF THE ACCOUNTING PERIOD'S ACTIVITIES

# 4.1 Operational statistics

Sperantonia statistics		The state of the s
	2018	2017
Number of members at the end of the accounting period	3,640	3,287
Number of beneficiaries at the end of the accounting period	8,512	7,922
Average number of members for the accounting period	3,441	3,250
Average age of beneficiaries for the accounting period	27.86	28.25
Pensioner ratio (beneficiaries > 65 years)	2,20%	2.22%
Average net contributions per member per month	R 4,183.78	R 4,429.66
Average net contributions per beneficiary per month	R 1,691.30	R 1,817.27
Average claims incurred per member per month	R 3,364.78	R 3,536.89
Average claims incurred per beneficiary per month	R 1,360.22	R 1,451.01
Average administration costs per member per month	R 200.56	R 212.35
Average administration costs per beneficiary per month	R 81.08	R 87.11
Average managed care: Management services per member		
per month	R 88.88	R 94.10
Accumulated funds per member at 31 December	R 44,887.09	R 49,123.31
Beneficiary ratio at 31 December	2.34	2.41
Net claims as a percentage of net contributions	80.42%	79.85%
Managed care: Management services as a percentage of gross	Э.	
contributions	2.12%	2.12%
Administration expenses as a percentage of gross	5.92%	5.92%

# 4.2 Results of operations

The results of the Scheme are set out in the financial statements and the Trustees believe that no further clarification is required.

#### 4.3 Accumulated funds ratio

	2018 R	2017 R
The accumulated funds ratio is calculated on the following Total members' funds per statement of financial position - Less: Available-for-sale reserve ** (Refer to next page)	175,689,014 (12,300,016)	149,341,258 (18,525,858)
Accumulated funds per Regulation 29	163,388,998	130,815,400
Annualised gross contributions	172,756,552	155,624,921
Accumulated funds ratio  = Accumulated funds/annualised gross contribution income x 100	94.58%	84.06%

(Registration no. 1526)

## REPORT OF THE BOARD OF TRUSTEES (continued)

#### 4.3 Accumulated funds ratio (continued)

\*\* Cumulative net gains on re-measurement to fair value are calculated as follows:

	2018 R	2017 R
Net cumulative gain at the beginning of the period	18,525,858	10,681,998
Unrealised gain on revaluation of available-for-sale investments included in accumulated funds	(994,322)	7,990,714
Realised gains on derecognition of available-for-sale investments	(5,231,520)	(146,854)
Cumulative net gain on remeasurement to fair value of available-for-sale investments included in accumulated funds	12,300,016	18,525,858

#### 4.4 Reserve accounts

Movements in the reserves are set out in the statement of changes in funds and reserves. There have been no unusual movements that the Trustees believe should be brought to the attention of the members of the Scheme.

## 4.5 Outstanding risk claims

Movements on the outstanding risk claims provision are set out in note 5 to the financial statements. There have been no unusual movements that the Trustees believe should be brought to the attention of the members of the Scheme.

#### 5 ACTUARIAL SERVICES

The Scheme's actuaries have been consulted in the determination of the contribution and benefit levels. The Scheme's actuaries also calculate the annual budget and monthly actuarial reports of the Scheme, including the monthly incurred but not yet reported (IBNR) claims provision.

# 6 EVENTS AFTER THE REPORTING DATE

There have been no events that occurred subsequent to the end of the accounting period that affect the financial statements and that the Trustees consider should be reported.

(Registration no. 1526)

## REPORT OF THE BOARD OF TRUSTEES (continued)

## 9 NON-COMPLIANCE MATTERS

#### 9.1 Contributions not received within three days of them becoming due

In terms of Section 26(7) of the Medical Schemes Act, of South Africa ("the Act"), all subscriptions or contributions shall be paid directly to a medical scheme not later than three days after payment thereof becoming due.

Although the majority of contribution payments were made within the stipulated payment deadlines, there were a small number of instances where the Scheme received contributions after three days of becoming due. These contributions equate to 0.29% of the gross contributions billed and were received within the month of them becoming due. Such arrear payments are outside the agreed contribution collection agreements with paying parties and are actively addressed as and when they occur.

The procedures that the Scheme follows for collection of these arrear contributions are aligned with its credit risk management policies.

## 9.2 Investment in participating employers and medical scheme administrators

At 31 December 2018, the Scheme indirectly held shares in MMI Holdings Limited amounting to R 321 992 (2017: R 93 280), Liberty Holdings Limited amounting to R 204 511 (2017: R 19 648) and Sanlam Limited amounting to R 871 164 (2017: R 381 256) and Discovery Holdings Limited amounting to R 2 479 214 in 2017.

Ordinarily this would be in contravention of Section 35(8) of the Act, which, inter alia, prohibits a medical scheme from investing any of its assets in an employer that participates in that scheme. However, as funds in these specific portfolios are structured at the sole discretion of the asset manager in a manner that maximizes the return on investment, and neither the Scheme nor these employers provide input into the structuring of the portfolio.

The Scheme has received exemption from the Council for Medical Schemes, from compliance this section of the Act.

## 9.3 Claims payments in excess of 30 days

Member or provider claims should be settled within 30 days of submission. Instances were noted where settlements took more than 30 days.

Instances were identified where claims that were processed on time had not passed for payment within 30 days. These are isolated cases and thus do not have a material effect on the Scheme.

The error is not expected to re-occur as internal quality assurance checks have been implemented to ensure payments are released timeously.

(Registration no. 1526)

# REPORT OF THE BOARD OF TRUSTEES (continued)

# 10 MEETING ATTENDANCE

The following schedules set out Board of Trustee meeting attendances and attendances by members of Sub-Committees:

Board of Trustees meetings	Number of meetings
Number of meetings for the year	6
C Hector	3
N Moonia - resigned 1 October 2018	3
D Radebe	-
E Hlophane	3
C Louw	4
S Sohan	5
K Madumo	4
J Meiring	4
JP Fegbeutel	6
V Vatsha-Mahlaba	6
Ms C McCrea-Phillips	5
Ms T Harakhchand	5
Ms K Kgomo - resigned 30 April 2018	1
Mr J Selumane	1
Mr S Hoon - appointed 10 June 2018	3
Mr M Gounden - appointed 1 October 2018	1
Ms G Shafee - appointed 1 October 2018	1
Attendees:	
AR Kelbrick - Principal Officer	6

(Registration no. 1526)

# REPORT OF THE BOARD OF TRUSTEES (continued)

# 10 MEETING ATTENDANCE (continued)

Audit and Risk Committee meetings	Number of meetings
Number of meetings for the year	2
S Moodley	2
C Bathauer	1
J Badenhorst	2
S Bisnath	2
C Dorasamy	2
C Hector	1

CHAIRMAN C HECTOR TRUSTEE S SOHAN PRINCIPAL OFFICER AR KELBRICK

23 April 2019